[1]
Whetten K, Reif S, Whetten R, Murphy-McMillan LK. Trauma, mental health, distrust, and stigma among HIV-positive persons: implications for effective care. Psychosomatic medicine. 2008 Jun:70(5):531-8. doi: 10.1097/PSY.0b013e31817749dc. Epub
[PubMed PMID: 18541904]
[2]
Snider WD, Simpson DM, Nielsen S, Gold JW, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Annals of neurology. 1983 Oct:14(4):403-18
[PubMed PMID: 6314874]
[3]
Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. 1985. Journal of neurosurgery. 2007 Dec:107(6):1253-73; discussion 1251
[PubMed PMID: 18077970]
[4]
Michaels SH,Clark R,Kissinger P, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The New England journal of medicine. 1998 Aug 6;
[PubMed PMID: 9696654]
[5]
Gisslén M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC infectious diseases. 2011 Dec 28:11():356. doi: 10.1186/1471-2334-11-356. Epub 2011 Dec 28
[PubMed PMID: 22204557]
[6]
Clifford DB. HIV-associated neurocognitive disorder. Current opinion in infectious diseases. 2017 Feb:30(1):117-122. doi: 10.1097/QCO.0000000000000328. Epub
[PubMed PMID: 27798498]
Level 3 (low-level) evidence
[7]
Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (London, England). 2007 Sep 12:21(14):1915-21
[PubMed PMID: 17721099]
[8]
Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 Dec 7:75(23):2087-96. doi: 10.1212/WNL.0b013e318200d727. Epub
[PubMed PMID: 21135382]
[9]
Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K, CASCADE Collaboration. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Annals of neurology. 2008 Feb:63(2):213-21
[PubMed PMID: 17894380]
[10]
Sacktor N, Skolasky R, Selnes OA, Watters M, Poff P, Shiramizu B, Shikuma C, Valcour V. Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals. Journal of neurovirology. 2007 Jun:13(3):203-9
[PubMed PMID: 17613710]
[11]
McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, Rosario D, Alexander TJ, Marra C, Ances BM, Grant I, CHARTER Group. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012 Feb 14:78(7):485-92. doi: 10.1212/WNL.0b013e3182478d64. Epub
[PubMed PMID: 22330412]
[12]
Moulignier A,Costagliola D, Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders. Current topics in behavioral neurosciences. 2021
[PubMed PMID: 31989463]
[13]
Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, Cherner M, Heaton R, Ellis R, Everall IP, Grant I, Masliah E, HIV Neurobehavioral Research Center Group. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. The Journal of infectious diseases. 2007 Aug 1:196(3):361-70
[PubMed PMID: 17597450]
[14]
Clifford DB, Vaida F, Kao YT, Franklin DR, Letendre SL, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Grant I, Heaton RK, CHARTER Group. Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology. 2015 Jan 20:84(3):241-50. doi: 10.1212/WNL.0000000000001156. Epub 2014 Dec 10
[PubMed PMID: 25503616]
[15]
Bharti AR, McCutchan A, Deutsch R, Smith DM, Ellis RJ, Cherner M, Woods SP, Heaton RK, Grant I, Letendre SL. Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Dec 15:63(12):1655-1660
[PubMed PMID: 27794019]
[16]
Levine AJ, Service S, Miller EN, Reynolds SM, Singer EJ, Shapshak P, Martin EM, Sacktor N, Becker JT, Jacobson LP, Thompson P, Freimer N. Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2012 Sep:159B(6):669-83. doi: 10.1002/ajmg.b.32071. Epub 2012 May 24
[PubMed PMID: 22628157]
[17]
Navia BA, Price RW. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Archives of neurology. 1987 Jan:44(1):65-9
[PubMed PMID: 3800724]
[18]
Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Annals of neurology. 1986 Jun:19(6):517-24
[PubMed PMID: 3729308]
[19]
Watkins CC, Treisman GJ. Cognitive impairment in patients with AIDS - prevalence and severity. HIV/AIDS (Auckland, N.Z.). 2015:7():35-47. doi: 10.2147/HIV.S39665. Epub 2015 Jan 29
[PubMed PMID: 25678819]
[20]
Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, Sacktor N, Schifitto G, Kieburtz K, Epstein L, Marder KS, Dana Consortium on the Therapy of HIV-Dementia and Related Cognitive Disorders. Factors associated with incident human immunodeficiency virus-dementia. Archives of neurology. 2001 Mar:58(3):473-9
[PubMed PMID: 11255452]
[21]
Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, Ragin A, Levine A, Miller E. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016 Jan 26:86(4):334-40. doi: 10.1212/WNL.0000000000002277. Epub 2015 Dec 30
[PubMed PMID: 26718568]
[22]
Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group, HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of neurovirology. 2011 Feb:17(1):3-16. doi: 10.1007/s13365-010-0006-1. Epub 2010 Dec 21
[PubMed PMID: 21174240]
[23]
Crum-Cianflone NF, Moore DJ, Letendre S, Poehlman Roediger M, Eberly L, Weintrob A, Ganesan A, Johnson E, Del Rosario R, Agan BK, Hale BR. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013 Jan 22:80(4):371-9. doi: 10.1212/WNL.0b013e31827f0776. Epub 2013 Jan 9
[PubMed PMID: 23303852]
[24]
Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology. 2006 May 19:3():28
[PubMed PMID: 16712719]
[25]
Lawrence DM, Major EO. HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes and infection. 2002 Mar:4(3):301-8
[PubMed PMID: 11909740]
[26]
Tucker KA, Robertson KR, Lin W, Smith JK, An H, Chen Y, Aylward SR, Hall CD. Neuroimaging in human immunodeficiency virus infection. Journal of neuroimmunology. 2004 Dec:157(1-2):153-62
[PubMed PMID: 15579293]
[27]
Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS (London, England). 2000 Jan 7:14(1):69-74
[PubMed PMID: 10714569]
Level 3 (low-level) evidence
[28]
Bell JE, Busuttil A, Ironside JW, Rebus S, Donaldson YK, Simmonds P, Peutherer JF. Human immunodeficiency virus and the brain: investigation of virus load and neuropathologic changes in pre-AIDS subjects. The Journal of infectious diseases. 1993 Oct:168(4):818-24
[PubMed PMID: 8376829]
[29]
Anthony IC, Crawford DH, Bell JE. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain : a journal of neurology. 2003 May:126(Pt 5):1058-67
[PubMed PMID: 12690046]
[30]
Budka H. Multinucleated giant cells in brain: a hallmark of the acquired immune deficiency syndrome (AIDS). Acta neuropathologica. 1986:69(3-4):253-8
[PubMed PMID: 3962603]
[31]
McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Annals of neurology. 2010 Jun:67(6):699-714. doi: 10.1002/ana.22053. Epub
[PubMed PMID: 20517932]
[32]
Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Annals of neurology. 1986 Jun:19(6):525-35
[PubMed PMID: 3014994]
[33]
Gallego L, Barreiro P, López-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS reviews. 2011 Jul-Sep:13(3):171-9
[PubMed PMID: 21799535]
[34]
. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991 Jun:41(6):778-85
[PubMed PMID: 2046917]
Level 3 (low-level) evidence
[35]
Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, Gisslén M, Angoff N, Price RW, Cinque P, Spudich S. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS (London, England). 2012 Sep 10:26(14):1765-74. doi: 10.1097/QAD.0b013e328355e6b2. Epub
[PubMed PMID: 22614889]
[36]
Pérez-Valero I, Ellis R, Heaton R, Deutsch R, Franklin D, Clifford DB, Collier A, Gelman B, Marra C, McCutchan JA, Navis A, Sacktor N, Simpson D, Grant I, Letendre S. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS (London, England). 2019 Mar 1:33(3):475-481. doi: 10.1097/QAD.0000000000002074. Epub
[PubMed PMID: 30702516]
[37]
Lescure FX, Moulignier A, Savatovsky J, Amiel C, Carcelain G, Molina JM, Gallien S, Pacanovski J, Pialoux G, Adle-Biassette H, Gray F. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 Jul:57(1):101-8. doi: 10.1093/cid/cit175. Epub 2013 Mar 20
[PubMed PMID: 23515205]
[38]
Sacktor N. Changing clinical phenotypes of HIV-associated neurocognitive disorders. Journal of neurovirology. 2018 Apr:24(2):141-145. doi: 10.1007/s13365-017-0556-6. Epub 2017 Jul 27
[PubMed PMID: 28752495]
[39]
Robertson K, Liner J, Heaton R. Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychology review. 2009 Jun:19(2):232-49. doi: 10.1007/s11065-009-9096-z. Epub 2009 May 20
[PubMed PMID: 19455425]
[40]
Thurnher MM, Donovan Post MJ. Neuroimaging in the brain in HIV-1-infected patients. Neuroimaging clinics of North America. 2008 Feb:18(1):93-117; viii. doi: 10.1016/j.nic.2007.12.013. Epub
[PubMed PMID: 18319157]
[41]
Chiang MC, Dutton RA, Hayashi KM, Lopez OL, Aizenstein HJ, Toga AW, Becker JT, Thompson PM. 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. NeuroImage. 2007 Jan 1:34(1):44-60
[PubMed PMID: 17035049]
[42]
Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur JC, Ronald A, Katabira E. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (London, England). 2005 Sep 2:19(13):1367-74
[PubMed PMID: 16103767]
[43]
Wojna V,Skolasky RL,Hechavarría R,Mayo R,Selnes O,McArthur JC,Meléndez LM,Maldonado E,Zorrilla CD,García H,Kraiselburd E,Nath A, Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. Journal of neurovirology. 2006 Oct;
[PubMed PMID: 17065128]
[44]
Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (London, England). 2010 Jun 1:24(9):1243-50. doi: 10.1097/QAD.0b013e3283354a7b. Epub
[PubMed PMID: 19996937]
[45]
Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 Apr:56(7):1004-17. doi: 10.1093/cid/cis975. Epub 2012 Nov 21
[PubMed PMID: 23175555]
Level 3 (low-level) evidence
[46]
Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. Journal of acquired immune deficiency syndromes (1999). 2007 Jun 1:45(2):174-82
[PubMed PMID: 17356465]
[47]
Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Archives of neurology. 2008 Jan:65(1):65-70. doi: 10.1001/archneurol.2007.31. Epub
[PubMed PMID: 18195140]
Level 1 (high-level) evidence
[48]
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA, HIV-CAUSAL Collaboration. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 2014 Jul 8:83(2):134-41. doi: 10.1212/WNL.0000000000000564. Epub 2014 Jun 6
[PubMed PMID: 24907236]
[49]
Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009 Aug 4:73(5):342-8. doi: 10.1212/WNL.0b013e3181ab2b3b. Epub 2009 May 27
[PubMed PMID: 19474412]
[50]
Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ, A5170 Study Team. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010 Apr 20:74(16):1260-6. doi: 10.1212/WNL.0b013e3181d9ed09. Epub 2010 Mar 17
[PubMed PMID: 20237308]
[51]
Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, Clifford DB, Best BM, May S, Umlauf A, Cherner M, Sanders C, Ballard C, Simpson DM, Jay C, McCutchan JA. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Apr:58(7):1015-22. doi: 10.1093/cid/cit921. Epub 2013 Dec 18
[PubMed PMID: 24352352]
Level 1 (high-level) evidence
[52]
Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. Journal of acquired immune deficiency syndromes (1999). 2009 Sep 1:52(1):56-63
[PubMed PMID: 19731418]
[53]
Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. The Journal of clinical psychiatry. 1994 Mar:55(3):92-7
[PubMed PMID: 7915270]
[54]
Perkins DO, Stern RA, Golden RN, Murphy C, Naftolowitz D, Evans DL. Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic. The American journal of psychiatry. 1994 Feb:151(2):233-6
[PubMed PMID: 8296895]
[55]
Hinkin CH, Castellon SA, Hardy DJ, Farinpour R, Newton T, Singer E. Methylphenidate improves HIV-1-associated cognitive slowing. The Journal of neuropsychiatry and clinical neurosciences. 2001 Spring:13(2):248-54
[PubMed PMID: 11449032]
[56]
Sewell DD, Jeste DV, Atkinson JH, Heaton RK, Hesselink JR, Wiley C, Thal L, Chandler JL, Grant I. HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. The American journal of psychiatry. 1994 Feb:151(2):237-42
[PubMed PMID: 8296896]
Level 3 (low-level) evidence
[57]
Parenti DM, Simon GL, Scheib RG, Meyer WA 3rd, Sztein MB, Paxton H, DiGioia RA, Schulof RS. Effect of lithium carbonate in HIV-infected patients with immune dysfunction. Journal of acquired immune deficiency syndromes. 1988:1(2):119-24
[PubMed PMID: 2975332]
[58]
Halman MH, Worth JL, Sanders KM, Renshaw PF, Murray GB. Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection. The Journal of neuropsychiatry and clinical neurosciences. 1993 Fall:5(4):430-4
[PubMed PMID: 8286943]
[59]
Dubé B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. Journal of psychiatry & neuroscience : JPN. 2005 Jul:30(4):237-46
[PubMed PMID: 16049567]
[60]
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Dec:53(11):1120-6. doi: 10.1093/cid/cir627. Epub 2011 Oct 13
[PubMed PMID: 21998278]
[61]
Carter SL, Rourke SB, Murji S, Shore D, Rourke BP. Cognitive complaints, depression, medical symptoms, and their association with neuropsychological functioning in HIV infection: a structural equation model analysis. Neuropsychology. 2003 Jul:17(3):410-9
[PubMed PMID: 12959507]
[62]
Shapiro ME, Mahoney JR, Zingman BS, Pogge DL, Verghese J. Apathy correlates with cognitive performance, functional disability, and HIV RNA plasma levels in HIV-positive individuals. Journal of clinical and experimental neuropsychology. 2013:35(9):934-45. doi: 10.1080/13803395.2013.838941. Epub 2013 Oct 4
[PubMed PMID: 24090038]
[63]
Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, González-García M, Moltó J, Negredo E, Clotet B. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS reviews. 2009 Apr-Jun:11(2):103-9
[PubMed PMID: 19529750]
[64]
Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I, CHARTER Group. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Feb 1:60(3):473-80. doi: 10.1093/cid/ciu862. Epub 2014 Oct 31
[PubMed PMID: 25362201]
[65]
Radtke KK, Bacchetti P, Anastos K, Merenstein D, Crystal H, Karim R, Weber KM, Edmonds A, Sheth AN, Fischl MA, Vance D, Greenblatt RM, Rubin LH. Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999). 2018 Jun 1:78(2):202-208. doi: 10.1097/QAI.0000000000001658. Epub
[PubMed PMID: 29762344]
[66]
Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. Psychological bulletin. 1993 May:113(3):472-86
[PubMed PMID: 8316610]
[67]
Farhadian S, Patel P, Spudich S. Neurological Complications of HIV Infection. Current infectious disease reports. 2017 Nov 21:19(12):50. doi: 10.1007/s11908-017-0606-5. Epub 2017 Nov 21
[PubMed PMID: 29164407]
[68]
Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I, CHARTER Group. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (London, England). 2011 Sep 10:25(14):1747-51. doi: 10.1097/QAD.0b013e32834a40cd. Epub
[PubMed PMID: 21750419]